Literature DB >> 19724059

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

Qing Zhou1, Christoph Bucher, Meghan E Munger, Steven L Highfill, Jakub Tolar, David H Munn, Bruce L Levine, Megan Riddle, Carl H June, Daniel A Vallera, Brenda J Weigel, Bruce R Blazar.   

Abstract

Tumor-induced immune suppression can permit tumor cells to escape host immune resistance. To elucidate host factors contributing to the poor response of adoptively transferred tumor-reactive cytotoxic T lymphocytes (CTLs), we used a systemic model of murine acute myeloid leukemia (AML). AML progression resulted in a progressive regulatory T-cell (Treg) accumulation in disease sites. The adoptive transfer of in vitro-generated, potently lytic anti-AML-reactive CTLs failed to reduce disease burden or extend survival. Compared with non-AML-bearing hosts, transferred CTLs had reduced proliferation in AML sites of metastases. Treg depletion by a brief course of interleukin-2 diphtheria toxin (IL-2DT) transiently reduced AML disease burden but did not permit long-term survival. In contrast, IL-2DT prevented anti-AML CTL hypoproliferation, increased the number of transferred CTLs at AML disease sites, reduced AML tumor burden, and resulted in long-term survivors that sustained an anti-AML memory response. These data demonstrated that Tregs present at AML disease sites suppress adoptively transferred CTL proliferation, limiting their in vivo expansion, and Treg depletion before CTL transfer can result in therapeutic efficacy in settings of substantial pre-existing tumor burden in which antitumor reactive CTL infusion alone has proven ineffective.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19724059      PMCID: PMC2773484          DOI: 10.1182/blood-2009-03-208181

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

Review 1.  Tregs and transplantation tolerance.

Authors:  Patrick T Walsh; Devon K Taylor; Laurence A Turka
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation.

Authors:  Erik Marijt; Amon Wafelman; Menno van der Hoorn; Cornelis van Bergen; Rian Bongaerts; Simone van Luxemburg-Heijs; Joost van den Muijsenberg; Judith Olde Wolbers; Nicole van der Werff; Roel Willemze; Frederik Falkenburg
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

3.  Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.

Authors:  Hisashi Imai; Masanao Saio; Kenichi Nonaka; Tatsuhiko Suwa; Naoki Umemura; Guan-Feng Ouyang; Jiro Nakagawa; Hiroyuki Tomita; Shinji Osada; Yasuyuki Sugiyama; Yosuke Adachi; Tsuyoshi Takami
Journal:  Cancer Sci       Date:  2007-03       Impact factor: 6.716

Review 4.  Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.

Authors:  Allison Blair; Nicholas J Goulden; Nathan A Libri; Anthony Oakhill; Derwood H Pamphilon
Journal:  Blood Rev       Date:  2005-04-07       Impact factor: 8.250

5.  Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.

Authors:  Brenda J Weigel; Angela Panoskaltsis-Mortari; Miechaleen Diers; Melissa Garcia; Chris Lees; Arthur M Krieg; Wei Chen; Bruce R Blazar
Journal:  Exp Hematol       Date:  2006-10       Impact factor: 3.084

Review 6.  Human tumor antigens, immunosurveillance, and cancer vaccines.

Authors:  Olivera J Finn
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

7.  Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients.

Authors:  Xingbing Wang; Jine Zheng; Jun Liu; Junxia Yao; Yanli He; Xiaoqing Li; Jingming Yu; Jing Yang; Zhongping Liu; Shiang Huang
Journal:  Eur J Haematol       Date:  2005-12       Impact factor: 2.997

8.  Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.

Authors:  Nicolas Larmonier; Marilyn Marron; Yi Zeng; Jessica Cantrell; Angela Romanoski; Marjan Sepassi; Sylvia Thompson; Xinchun Chen; Samita Andreansky; Emmanuel Katsanis
Journal:  Cancer Immunol Immunother       Date:  2006-04-13       Impact factor: 6.968

Review 9.  Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives.

Authors:  R Zeiser; H Bertz; A Spyridonidis; L Houet; J Finke
Journal:  Bone Marrow Transplant       Date:  2004-12       Impact factor: 5.483

Review 10.  Tregs and allergic disease.

Authors:  Douglas S Robinson; Mark Larché; Stephen R Durham
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

View more
  55 in total

Review 1.  Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation.

Authors:  Michael R Verneris; Michael J Burke
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

2.  Scaffold protein Disc large homolog 1 is required for T-cell receptor-induced activation of regulatory T-cell function.

Authors:  Alexandra Zanin-Zhorov; Jiqiang Lin; Jose Scher; Sudha Kumari; David Blair; Keli L Hippen; Bruce R Blazar; Steven B Abramson; Juan J Lafaille; Michael L Dustin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

3.  Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.

Authors:  Merav Bar; Megan Othus; Hanahlyn M Park; Vicky Sandhu; Xueyan Chen; Brent L Wood; Elihu Estey
Journal:  Leuk Lymphoma       Date:  2015-05-12

4.  A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Authors:  Sarah Nikiforow; Haesook T Kim; Heather Daley; Carol Reynolds; Kyle Thomas Jones; Philippe Armand; Vincent T Ho; Edwin P Alyea; Corey S Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

Review 5.  Minimal residual disease following allogeneic hematopoietic stem cell transplantation.

Authors:  Nicolaus Kröger; Koichi Miyamura; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-01       Impact factor: 5.742

Review 6.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors:  Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

Review 7.  Umbilical cord blood graft engineering: challenges and opportunities.

Authors:  P A Thompson; K Rezvani; C M Hosing; B Oran; A L Olson; U R Popat; A M Alousi; N D Shah; S Parmar; C Bollard; P Hanley; P Kebriaei; L Cooper; J Kellner; I K McNiece; E J Shpall
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 8.  Programmed death-1 checkpoint blockade in acute myeloid leukemia.

Authors:  Alison Sehgal; Theresa L Whiteside; Michael Boyiadzis
Journal:  Expert Opin Biol Ther       Date:  2015-06-03       Impact factor: 4.388

9.  SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.

Authors:  Abhishek K Srivastava; Gunes Dinc; Rajesh K Sharma; Esma S Yolcu; Hong Zhao; Haval Shirwan
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

Review 10.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.